ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO228

Multiparametric Magnetic Resonance Imaging Allows the Prediction of Diabetic Kidney Disease Progression

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Makvandi, Kianoush, Sahlgrenska universitetssjukhuset, Goteborg, Sweden
  • Hockings, Paul, Antaros Medical, Gotenburg, Sweden
  • Jensen, Gert, Sahlgrenska universitetssjukhuset, Goteborg, Sweden
  • Hulthe, Johannes, Antaros Medical, Gotenburg, Västra Götaland, Sweden
  • Haraldsson, Henrik, Antaros Medical, Gotenburg, Västra Götaland, Sweden
  • Baid-Agrawal, Seema, Sahlgrenska universitetssjukhuset, Goteborg, Sweden
Background

We recently showed that a comprehensive non-contrast multiparametric Magnetic Resonance Imaging (mpMRI) allowed functional and structural assessment of diabetic kidney disease (DKD). We further investigated whether the MRI biomarkers could predict disease progression.

Methods

In this prospective study, 38 DKD subjects aged 18–79 years and 20 age- and gender-matched healthy volunteers (HV) were included at baseline. 31 DKD subjects (2 stage 2, 13 stage 3, 14 stage 4, and 2 stage 5) and 17 HV were reexamined at 2 years ± 6 months. Clinical examination, iohexol clearance for measured glomerular filtration rate (mGFR), urine albumin:creatinine ratio and mpMRI were done at both visits. A wide range of MRI biomarkers associated with kidney hemodynamics, oxygenation and macro/microstructure were evaluated. Disease progression was defined by at least one of the following at 2 years: a) decrease in mGFR slope of >5 mL/year/1.73m2, b) worsening UACR category or c) any major adverse kidney event defined as sustained decrease in eGFR of >40%/doubling of serum creatinine from baseline, development of kidney failure with mGFR <15 ml/min/1.73m2 or death from renal cause. Univariable logistic regression analyses were performed to discriminate between progressors and non-progressors using each imaging endpoint as a predictor variable.

Results

Mean 2-year mGFR decline (ml/min/1.73m2) in DKD patients was -2.7± 5.37 and in HV -1.9 ± 10.71. R1 cortex (measure of longitudinal nuclear MR relaxation rate for molecular environment) showed an area under ROC curve of 0.88 (p=0.0074) in DKD subjects (Figure 1) and 0.69 (p=0.032) in the whole population.

Conclusion

The imaging biomarker R1 cortex, which reflects molecular environment- viscosity, fibrosis and inflammation (interstitial oedema, cellular swelling) showed significant predictive property for progression of DKD. A confirmatory study with R1 cortex as a pre-specified endpoint is required to confirm these results.

Figure 1. ROC-curve of R1 cortex for predicting progression in DKD patients who have progressed according to at least one of criteria defined in a, b or c

Funding

  • Commercial Support –